

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2022/076910 A1**

(43) International Publication Date  
14 April 2022 (14.04.2022)

(51) International Patent Classification:

C07K 14/705 (2006.01) C12N 5/0783 (2010.01)  
C07K 14/725 (2006.01) C12N 5/074 (2010.01)

Published:

— with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2021/054302

(22) International Filing Date:

08 October 2021 (08.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/090,113 09 October 2020 (09.10.2020) US  
63/172,383 08 April 2021 (08.04.2021) US

(71) Applicant: **FATE THERAPEUTICS, INC.** [US/US];  
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(72) Inventors: **LU, Dan**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **VALAMEHR, Bahram**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **PERALTA, Eigen**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **LEE, Tom**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **WITTY, Alec**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(74) Agent: **GIERING, Jeffery, C.** et al.; Greenberg Traurig, LLP, 18565 Jamboree Road, Suite 500, Irvine, CA 92612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ENGINEERED IPSC AND ARMED IMMUNE EFFECTOR CELLS

(57) Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

WO 2022/076910 A1